-
![3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2016/08/04/US20160221972A1/abs.jpg.150x150.jpg)
1.发明申请3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开3-ALKYL BICYCLIC [4,5,0]氢氧化物作为HDAC抑制剂公开(公告)号：US20160221972A1
公开(公告)日：2016-08-04
申请号：US15013820
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David Lancia, JR. , David S. Millan , Matthew W. Martin , Kenneth W. Bair
IPC: C07D267/14 , C07D417/04 , C07D413/14 , C07D413/06 , C07D413/12 , C07D498/08 , C07D498/04 , C07D243/14 , C07D403/06 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/10 , C07D471/04 , C07D405/06 , C07D413/04
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本公开涉及可用于治疗与HDAC相关的疾病或病症的锌依赖性组蛋白脱乙酰酶（HDAC）的抑制剂，例如具有式I的HDAC6：其中R，L，X 1，X 2，X 3，X 4， Y1，Y2，Y3和Y4。
-
2.发明申请公开(公告)号：US20160229864A1
公开(公告)日：2016-08-11
申请号：US15015563
申请日：2016-02-04
Applicant: Forma Therapeutics, Inc.
Inventor： Stephanos Ioannidis , Adam Charles Talbot , Bruce Follows , Alexandre Joseph Buckmelter , Minghua Wang , Ann-Marie Campbell , David Lancia, JR.
IPC: C07D495/04
CPC classification number: C07D495/04 , A61K31/519
Abstract: The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R5, R5′, X1, X2, n, and m are described herein.
Abstract translation: 本公开涉及可用于治疗癌症，神经变性疾病，免疫疾病，炎性疾病，心血管疾病，缺血性疾病，病毒感染和疾病以及细菌感染和疾病的USP7抑制剂的抑制剂，其具有下式：其中R1，R2， R3，R5，R5'，X1，X2，n和m。
-
Patent Agency Ranking
3.发明申请QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS 有权喹诺酮和亚氨基胆碱作为UBIQUITIN特异性蛋白酶7抑制剂公开(公告)号：US20160229833A1
公开(公告)日：2016-08-11
申请号：US15015571
申请日：2016-02-04
Applicant: Forma Therapeutics, Inc.
Inventor： Stephanos Ioannidis , Adam Charles Talbot , Bruce Follows , Alexandre Joseph Buckmelter , Minghua Wang , Ann-Marie Campbell , David Lancia, JR.
IPC: C07D401/06 , C07D471/04
CPC classification number: C07D401/06 , C07D239/88 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R4′, X1, Y1, Y2, Y3, Y4, n, and m are described herein.
Abstract translation: 本公开内容涉及可用于治疗癌症，神经变性疾病，免疫疾病，炎症性疾病，心血管疾病，缺血性疾病，病毒感染和疾病以及细菌感染和疾病的USP7抑制剂的抑制剂，其具有下式：其中R1，R2 ，R3，R4，R4'，X1，Y1，Y2，Y3，Y4，n和m。
-
![3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2016/08/04/US20160222028A1/abs.jpg.150x150.jpg)
4.发明申请3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开3-ALKYL-4-AMIDO-BICYCLIC [4,5,0]氢氧化物作为HDAC抑制剂公开(公告)号：US20160222028A1
公开(公告)日：2016-08-04
申请号：US15013814
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David Lancia, JR. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: C07D498/04 , C07D267/14 , C07D493/08 , C07D243/14 , C07D495/10 , C07D413/08 , C07D413/14 , C07D413/06 , C07D491/107
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本公开涉及可用于治疗与HDAC相关的疾病或病症的锌依赖性组蛋白脱乙酰酶（HDAC）的抑制剂，例如具有式I的HDAC6：其中R，L，X 1，X 2，X 3，X 4， Y1，Y2，Y3和Y4。
-
5.发明申请PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS 有权吡咯和吡唑并嘧啶作为UBIQUITIN特异性蛋白酶7抑制剂公开(公告)号：US20160185785A1
公开(公告)日：2016-06-30
申请号：US14982127
申请日：2015-12-29
Applicant: Forma Therapeutics, Inc.
Inventor： Stephanos Ioannidis , Adam Charles Talbot , Bruce Follows , Alexandre Joseph Buckmelter , Minghua Wang , Ann-Marie Campbell , Darby Rye Schmidt , David Joseph Guerin , Justin A. Caravella , R. Bruce Diebold , Anna Ericsson , David Lancia, JR.
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , A61K31/519 , C07D519/00
Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5′ and R6 are described herein.
Abstract translation: 本发明涉及可用于治疗癌症，神经变性疾病，免疫疾病，炎症性疾病，心血管疾病，缺血性疾病，病毒感染和疾病以及细菌感染和疾病的USP7抑制剂的抑制剂，其具有下式：其中m，n， 本文描述了X1，X2，R1-R5，R5'和R6。
-
![3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2016/08/04/US20160222022A1/abs.jpg.150x150.jpg)
6.发明申请3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开3-ARYL-4-AMIDO-BICYCLIC [4,5,0]氢氧化物作为HDAC抑制剂公开(公告)号：US20160222022A1
公开(公告)日：2016-08-04
申请号：US15013816
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David Lancia, JR. , David S. Millan , Matthew W. Martin
IPC: C07D493/08 , C07D267/14 , C07D413/14 , C07D413/06
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本公开涉及可用于治疗与HDAC相关的疾病或病症的锌依赖性组蛋白脱乙酰酶（HDAC）的抑制剂，例如具有式I的HDAC6：其中R，L，X 1，X 2，X 3，X 4， Y1，Y2，Y3和Y4。
-
![3-ARYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2016/08/04/US20160221973A1/abs.jpg.150x150.jpg)
7.发明申请3-ARYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开3-ARYL BICYCLIC [4,5,0]氢氧化物作为HDAC抑制剂公开(公告)号：US20160221973A1
公开(公告)日：2016-08-04
申请号：US15013826
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David Lancia, JR. , David S. Millan , Matthew W. Martin
IPC: C07D267/14 , C07D413/12 , C07D413/04 , C07D413/06
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本发明涉及可用于治疗与HDAC6相关的疾病或病症的锌依赖性组蛋白脱乙酰酶（HDAC）的抑制剂，其具有式I：其中R，L，X 1，X 2，X 3，X 4，Y 1，Y 2，Y 3 ，和Y4。
-
-
-
-
-
-
Search Results
7
records
(took 0.024 seconds)
